Justification of metformin hydrochloride biowaiver criteria based on bioequivalence study

Abstract

The Biopharmaceutics Classification System (BCS) represents the framework for predicting the intestinal drug absorption based on its solubility and intestinal permeability. Recent research has lead to the use of in vitro tests to waive additional in vivo bioequivalence studies for some pharmaceutical products (i. e. biowaiver). The current regulations permit waivers for BCS Class I (highly soluble/highly permeable) drug substances, which represent up to 25 % of the drugs. Efforts in both the science and regulatory bodies are being made to extend biowaivers to certain Class II and III products, which would represent more than 50 % of all drugs coming to the market. The aim of this study was to investigate the influence of experimental conditions on metformin hydrochloride (CAS 1115-70-4) release from two immediate-release tablet formulations with proven bioequivalence and justify the biowaiver request for dissolution profile similarity in three pH media.

The results obtained indicate that differences in drug dissolution observed in vitro were not reflected in vivo. Such data support the existing idea that BCS Class III drugs are eligible biowaiver candidates, even if a very rapid dissolution criterion is not fulfilled.

Key words

Antihyperglycemic drug - BCS Class III drugs - CAS 1115-70-4 - In vitro - in vivo correlation - Metformin hydrochloride, bioequivalence, dissolution, immediate-release

• References

• 1 Note for guidance on the investigation of bioavailability and bioequivalence, CPMP/EWP/QWP/1401/98. Rev. 1, July 2008
• 2 Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products – general considerations, US Department of Health and Human Services, CDER/FDA, March 2003
• 3 Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms containing certain active moietes/active ingredients based on a Biopharmaceutics Classification System, CDER/FDA; January 1999
• 4 WHO Expert Committee on Specifications for Pharmaceutical Preparations, Fortieth Report (WHO TRS No. 937): Annex 7: Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish inter-changeability, Annex 8: Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms, Annex 9: Additional guidance for organizations performing in vivo bioequivalence studies; May 2006
• 5 Blume HH, Schug BS. The biopharmaceutics classification system (BCS): Class III drugs-better candidate for BA/BE waiver?. Eur J Pharm Sci. 1999; 9: 117-21
• 6 Yu LX, Amidon GL, Polli IE, Zhao H, Metha MU, Conner DP et al Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 2002; 19: 921-5
• 7 Martindale, The Extra Pharmacopoeia. 36th ed. Sean C Sweetman. editor. London: The Pharmaceutical Press; 2009: 453-4
• 8 Campbell IW. Metformin and the United Kingdom prospective diabetes study: a commentary. Arq Bras Endocrinol Metab. 2000; 44 (2) 121-4
• 9 Chou CH. Uptake and dispersion of metformin in the isolated perfused rat liver. J Pharm Pharmacol. 2000; 52 (8) 1011-6
• 10 Custodio IM, Benet LZ. The intestinal absorption of metformin, a BCS Class III compound, is mediated by multiple transporters including the Plasma Membrane Monoamine Transporter (PMAT) and the Organic Cation Transporter (OCT1). AAPS Annual Meeting and Exposition, 16–20 November 2008
• 11 Sambol NC, Brookes LG, Chiang I, Goodman AM, Lin ET, Liu CY et al Food intake and dosage level, but not tablet vs. solution dosage form, affect the absorption of metfor-mina HCl in man. Br J Clin Pharmacol. 1996; 42: 510-2
• 12 Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH. Bio-waiwer extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm. Sci. 2004; 22 (4) 297-304
• 13 Charles BG, lacobsen NW, Ravenscroft PJ. Rapid liquid-chromatographic determination of metformin in plasma and urine. Clin Chem. 1981; 27: 434-6
• 14 Flores-Murrieta FJ, Aguilar-Cota ME, Camacho A, Reyes-García G, Herrera IE, Medina-Santillán R. Comparative bioavailability of two oral formulations manufactured in Mexico containing glyburide and metformin in diabetic patients. Proc West Pharmacol Soc. 2003; 46: 82-4
• 15 Kolte BL, Raut BB, Deo AA, Bagool MA, Shinde DB. Simultaneous determination of metformin in combination with rosiglitazone by reversed-phase liquid chromatography. J Chromatogr Sci. 2004; 42: 70-3
• 16 Moffat AC, Osselton MD, Widdop B. Metformin. In: Clarke’s Analysis of Drugs and Poisons. London: Pharmaceutical Press; 2004: 1229-30
• 17 Aburuz S, Millership I, McElnay I. The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, glicla-zide, glibenclamide or glimepiride in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 817 (2) 277-86
• 18 Wagner IG, Nelson E. Percent absorbed time plots derived from blood level and/or urinary excretion data. / Pharm Sci. 1963; 52: 610-1
• 19 Balan G, Timmins P, Greene D, Marathe PH. In vitro - in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. J Pharm Sci. 2001; 90 (8) 1176-85
• 20 Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharm. 1981; 12: 235-46
• 21 Moore JW, Flanner HH. Mathematical comparison of curves with an emphasis on in-vitro release profiles. Pharm Tech. 1996; 20: 64-74
• 22 Atanasova I, Bozhinova K, Todorova D, Terziivanov D. Pharmacokinetics and comparative bioavailability of two metformin formulations after single-dose administration in healthy subjects. Clin Drug Invest. 2003; 23 (11) 743-9
• 23 Bhavesh D, Chetan G, Bhat KM. Shivprakash. Estimation and pharmacokinetics of metformin in human voluntters. Indian J Pharm Educ Res. 2007; 41 (2) 135-9
• 24 Zhong G, Bi H, Zhou S, Chen X, Huang M. Simultaneous determination of metformin and gliclazide in human plasma by liquid chromatography-tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy volunteers. J Mass Spectrom. 2005; 40: 1462-71
• 25 Al Hawari S, AlGaai E, Yusuf A, Abdelgaleel A, Hammami MM. Bioequivalence study of two metformin formulations. Arzneimittelforschung. 2007; 57 (4) 192-5
• 26 Scheen AJ. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 1996; 30: 359-71
• 27 Sörgel F, Arnold G, Kinzig-Schippers M, Sauber C, Holz-grabe U, Rüsing G et al How reproducible are metformin levels from oral formulations of different manufacturing sites? AAPS Annual Meeting 1998. Available from: http:www.aapsj.org/abstracts/am_1998/3442.html
• 28 Yu LX, Ellison CD, Conner DP, Lesko LJ, Hussain AS. Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs. AAPS Pharm Sci. 3 (3) article 24 2001; DOI: 10.1208/ps030324.